Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > A little change...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by TheTruth1234on Nov 13, 2023 2:42pm
100 Views
Post# 35732575

RE:A little change...

RE:A little change...
Boomskid wrote: I have asked Stockhouse to cancel my Boomskid alias. As I have done in the past, if I get a new alias I will announce it. (I have not asked to have my posts removed nor would they do it if I did ask. They only do it for cause, as they did with digitel, prophetoffacts, etc.)

It's clear that some shareholders would like to see something happen with Bioasis, one way or the other. I have thousands of documents, emails, links and personal journal entries that may be of help if you want to take action. I would help the cause but I won't do it without compensation unless I am forced to by regulators. Regulators may need some of my documentation in order to understand the need to look deeper.

Bye...


The funny thing is ol' Johnny boy thinks people actually care he is leaving stockhouse!!

LMFAO.

News flash Johnny boy  No One Cares!!!


Now go back to being bankrupt Johnny boy!

Pssssssst, remember folks "its only a loss when you sell"!!!!!



LMFAO
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities